Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

prasugel vs ticagrelor angioplastyNo randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out in the last 7 years since these newer P2Y12 inhibitors first showed a higher efficacy relative to clopidogrel.

 

This study was designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with acute myocardial infarction treated with primary angioplasty.

 

A total of 1230 patients were enrolled and randomized to receive one drug or the other; treatment begun before the procedure.

 

Nearly 4% of infarctions were in cardiogenic shock and 5.2% required mechanical ventilation.

 

The primary endpoint was defined as death, re-infarction, urgent revascularization, stroke, major bleeding or extended hospitalization (beyond 7 days).

 

This analysis presents data from the first 30 days, but the total follow-up planned is 1 year and will be completed by 2017.

 

The study was prematurely terminated due to the wide similarity between these drugs. The primary endpoint was 4% for prasugrel vs. 4.1% for ticagrelor (odds ratio [OR]: 0.98; 95% confidence interval [CI]: 0.55 to 1.73; p = 0.939). No significant difference was observed in any of the different components of the primary endpoint.

 

At 30 days, the secondary endpoint composed of cardiovascular death, non-fatal infarction, or stroke did not show any significant difference between these drugs (prasugrel 2.7% vs. ticagrelor 2.5%; OR: 1.06; p = 0.864).

 

Conclusion

This head-to-head comparison of prasugrel and ticagrelor did not show any difference between these drugs regarding efficacy or safety in patients with acute myocardial infarction undergoing primary angioplasty.

 

The rates of major events were similar, although with broad confidence intervals around the estimates. In consequence, these observations must be confirmed in a larger study.

 

Original title: Prasugrel Versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Multicenter Randomized PRAGUE-18 Study.

Reference: Motovska Z et al. Circulation. 2016 Nov 22;134(21):1603-1612.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...